Visual Instillation of Sphenopalatine-block Intervention for ONgoing Migraine (VISION)
The goal of this double-blinded, randomized placebo controlled clinical trial is to to see if using a numbing medicine (lidocaine) on certain areas inside the nose can help with headaches, neck pain, facial pain and pressure, and other symptoms. It also aims to understand the pathophysiology that causes these symptoms.
The main questions it aims to answer are:
- Is applying numbing medication directly to the sphenopalatine ganglion (SPG) area, while watching through the scope to make sure it's in the right place, a workable and effective way to treat migraine headaches immediately and 24 hours?
- Is applying numbing medication directly to the sphenopalatine ganglion (SPG) area, while watching through the scope to make sure it's in the right place, a workable and effective way to improve patient-reported outcomes?
The 2-month study requires:
- One virtual visit (on the computer)
- One visit to the office for placement of the numbing medicine under direct vision
- Daily headache diary entries that take less than two minutes to complete
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Study Coorinator
- 电话号码:413-200-8634
- 邮箱:Visionstudy@migrainedisorders.org
学习地点
-
-
Massachusetts
-
Springfield、Massachusetts、美国、01107
- Ear, Nose, & Throat Surgeons of Western New England
-
接触:
- Study Coordinator
- 电话号码:413-200-8634
- 邮箱:Visionstudy@migrainedisorders.org
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion criteria:
- Aged 18 years or older
- Any race
- Any gender
At least 2 of 3 positives (a, b, c) below on the ID Migraine Screener from the American Headache Society:
- Photophobia
- Inability to function
- Nausea
- At least 3 months of patient-reported episodic or persistent discomfort, pain, or pressure in the anatomic distribution of the paranasal sinuses, orbits, or nasal cavities.
- The patient experiences at least 10 days of headaches and/or FPP within a 30-day period, during the run-in phase.
- No evidence of abnormal sinus findings on imaging [paranasal sinus CT, including cone beam imaging, or MRI (MRI images must include all paranasal sinuses) obtained when symptomatic in the last 12 months prior to presentation. Normal imaging findings included isolated mucus retention cysts 2 cm or less in size and minimal non-circumferential (isolated areas) mucosal thickening (3mm or less).
- Normal endoscopy if performed prior to enrollment, defined as the absence of purulent (opaque - white or other discolored - secretions) at the middle meatus or sphenoethmoid recess or nasal polyp disease.
- Daily access to a cell phone that can function with the study mobile application
- For women of child bearing potential: not pregnant and using a method of contraception during the duration of the study.
- The patient can be taking interventional and preventive medications and other treatments before and during the study period, including new medications which will be tracked. The clinical coordinator will ask the patient to refrain from taking any abortive medication, cannabis, and psilocybin 24 hours prior to the procedure visit.
Exclusion criteria:
- Prior endoscopic sinus surgery within the 3 months prior to enrollment.
- Nasal endoscopy if performed prior to enrollment shows severe signs of mucosal infection, (mucopurulent drainage) or nasal polyposis.
- A history of anterior skull base neoplasia.
- Nasal endoscopy if performed prior to enrollment does not allow visualization of the middle turbinate on endoscopy bilaterally after application of a topical decongestant.
- Signs of active or chronic sinusitis on CT (>3mm mucosal thickening or air fluid level in any paranasal sinus.)
- The patient cannot tolerate the use of topical anesthetics or intranasal endoscopy without sedation or general anesthesia
- Unable to see the middle meatus with either a nasal speculum or an endoscope
- Allergy to lidocaine or other local anesthetics (tertiary amine class 1b).
- Is currently using a schedule II narcotic for migraine pain.
- Current cocaine use or cocaine use within the last 30 days.
- Currently immunocompromised
- History or evidence of any other unstable or clinically significant medical condition that in the opinion of the sponsor-investigator/ Principal Investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
- Has received any investigational agent within 30 days of enrollment.
- Plans to participate in a concurrent clinical trial.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Topical lidocaine endoscopically-guided intranasal nerve block
Topical solution of 4% lidocaine on small cotton pledgets with be placed endoscopically at the posterior root of the middle turbinate and in the anterior ethmoid nerve region bilaterally for Sphenopalatine Ganglion Block (SPG) block with anterior ethmoid (AE) block.
|
A rigid endoscopic technique utilizing a cotton pledget as a delivery vehicle of the topical lidocaine allows direct visualization of the target.
|
|
安慰剂比较:Placebo (saline) endoscopically-guided intranasal nerve block
Topical solution of saline on small cotton pledgets with be placed endoscopically at the posterior root of the middle turbinate and in the anterior ethmoid nerve region bilaterally for Sphenopalatine Ganglion Block (SPG) block with anterior ethmoid (AE) block.
|
A rigid endoscopic technique utilizing cotton pledget as a delivery vehicle of the topical saline allows direct visualization of the target.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Acute headache pain
大体时间:Immediately before (pre-treatment) and after the endoscopy procedure at Visit 2, approximately 1 month after enrollment.
|
Acute headache pain will be measured using a 0 to 10 Likert scale (0 representing No Pain, and 10 representing the worst pain possible), before (pre-treatment) and after the endoscopy procedure (post-treatment) at 15, 30, 60 min and 24 hours.
|
Immediately before (pre-treatment) and after the endoscopy procedure at Visit 2, approximately 1 month after enrollment.
|
|
Acute facial pain or pressure
大体时间:Immediately before (pre-treatment) and after the endoscopy procedure at Visit 2, approximately 1 month after enrollment.
|
Acute facial pain or pressure will be measured using a 0 to 10 Likert scale (0 representing No Pain, and 10 representing the worst pain possible), before (pre-treatment) and after the endoscopy procedure (post-treatment) at 15, 30, 60 min and 24 hours.
|
Immediately before (pre-treatment) and after the endoscopy procedure at Visit 2, approximately 1 month after enrollment.
|
|
Acute neck pain
大体时间:Immediately before (pre-treatment) and after the endoscopy procedure at Visit 2, approximately 1 month after enrollment.
|
Acute neck pain will be measured using a 0 to 10 Likert scale (0 representing No Pain, and 10 representing the worst pain possible), before (pre-treatment) and after the endoscopy procedure (post-treatment) at 15, 30, 60 min and 24 hours.
|
Immediately before (pre-treatment) and after the endoscopy procedure at Visit 2, approximately 1 month after enrollment.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Headache days per month
大体时间:Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
|
Daily headache pain recorded in a mobile application.
Recorded as binary (Yes/No) and rated using a 0 to 10 Likert scale (0 representing No Pain, and 10 representing the worst pain possible).
|
Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
|
|
Facial pain or pressure days per month
大体时间:Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
|
Daily facial pain or pressure recorded in a mobile application.
Recorded as binary (Yes/No) and rated using a 0 to 10 Likert scale (0 representing No Pain or pressure, and 10 representing the worst pain or pressure possible).
|
Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
|
|
Neck pain days per month
大体时间:Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
|
Daily neck pain recorded in a mobile application.
Recorded as binary (Yes/No) and rated using a 0 to 10 Likert scale (0 representing No Pain, and 10 representing the worst pain possible).
|
Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
|
|
Sinonasal Outcome Test- 22 (SNOT-22)
大体时间:Immediately before the treatment at 1 month and again 1 month after treatment.
|
SNOT-22 is A validated 22-item questionnaire that measures the health-related quality of life (HRQoL) of patients with chronic rhinosinusitis (CRS).
The SNOT-22 is scored by adding the individual values of 22 symptom and quality-of-life items.
Each item is graded on a scale from 0 to 5, yielding a total cumulative score between 0 and 110, where higher numbers reflect more severe symptoms and a greater impact on health.
|
Immediately before the treatment at 1 month and again 1 month after treatment.
|
|
Migraine Disability Assessment (MIDAS)
大体时间:Immediately before the treatment at 1 month and again 1 month after treatment.
|
MIDAS is a valid and reliable short questionnaire for assessment of headache related disability. Respondents will enter the total number of days affected in the last one month for: Work or school: Days missed. Work or school productivity: Days where productivity was reduced by half or more. Household work: Days missed. Household work productivity: Days where productivity was reduced by half or more. Family, social, or leisure activities: Days missed. |
Immediately before the treatment at 1 month and again 1 month after treatment.
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Additional headache symptoms
大体时间:Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
|
Additional headache symptoms recorded in a mobile application.
Recorded as binary (Yes/No) and rated using a 0 to 10 Likert scale (0 representing No Pain, and 10 representing the worst pain possible).
|
Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
|
|
Rescue medications
大体时间:Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
|
Rescue medication needed, recorded in a mobile application.
Recorded as binary (Yes/No).
|
Daily, following enrollment to right before the treatment at 1 month and again from right after the treatment to 1 month after treatment.
|
合作者和调查者
调查人员
- 首席研究员:Jerry Schreibstein, MD、Ear, Nose, & Throat Surgeons of Western New England
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.